JP6263707B2 - 高コレステロール血症の治療方法 - Google Patents
高コレステロール血症の治療方法 Download PDFInfo
- Publication number
- JP6263707B2 JP6263707B2 JP2014095457A JP2014095457A JP6263707B2 JP 6263707 B2 JP6263707 B2 JP 6263707B2 JP 2014095457 A JP2014095457 A JP 2014095457A JP 2014095457 A JP2014095457 A JP 2014095457A JP 6263707 B2 JP6263707 B2 JP 6263707B2
- Authority
- JP
- Japan
- Prior art keywords
- fat
- group
- calebin
- cholesterol
- density lipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000035150 Hypercholesterolemia Diseases 0.000 title description 19
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 18
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 18
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 17
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 50
- 235000019197 fats Nutrition 0.000 description 45
- UYEWRTKHKAVRDI-UHFFFAOYSA-N Calebin A Natural products C1=C(O)C(OC)=CC(C=CC(=O)COC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-UHFFFAOYSA-N 0.000 description 34
- UYEWRTKHKAVRDI-ASVGJQBISA-N Calebin A Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)COC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-ASVGJQBISA-N 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 28
- 235000009200 high fat diet Nutrition 0.000 description 23
- 241000124008 Mammalia Species 0.000 description 20
- 235000012000 cholesterol Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 9
- 230000006698 induction Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930184164 Calebin Natural products 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- JZBRFIUYUGTUGG-UHFFFAOYSA-J tetrapotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JZBRFIUYUGTUGG-UHFFFAOYSA-J 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/259,404 | 2014-04-23 | ||
| US14/259,404 US9668999B2 (en) | 2014-04-23 | 2014-04-23 | Method for the treatment of hypercholesterolemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015209424A JP2015209424A (ja) | 2015-11-24 |
| JP2015209424A5 JP2015209424A5 (enExample) | 2016-06-16 |
| JP6263707B2 true JP6263707B2 (ja) | 2018-01-24 |
Family
ID=50828681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014095457A Expired - Fee Related JP6263707B2 (ja) | 2014-04-23 | 2014-05-02 | 高コレステロール血症の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9668999B2 (enExample) |
| EP (1) | EP2937084B1 (enExample) |
| JP (1) | JP6263707B2 (enExample) |
| KR (1) | KR101647549B1 (enExample) |
| AU (1) | AU2014202312B2 (enExample) |
| CA (2) | CA2850999C (enExample) |
| EA (1) | EA027148B1 (enExample) |
| MY (1) | MY170067A (enExample) |
| PH (1) | PH12014000244A1 (enExample) |
| PL (1) | PL2937084T3 (enExample) |
| TW (1) | TWI622394B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503805XA (en) * | 2015-04-19 | 2016-11-29 | Sabinsa Corp | Calebin A For Hepatic Steatosis |
| US9539232B1 (en) * | 2016-08-04 | 2017-01-10 | Muhammed Majeed | Calebin A for osteoporosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060352C (zh) * | 1996-02-08 | 2001-01-10 | 袁克兴 | 降脂药及其制备方法 |
| US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
| WO2001030335A2 (en) * | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| US20020012733A1 (en) | 2000-04-12 | 2002-01-31 | The Procter & Gamble Company | Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels |
| JP2005232059A (ja) * | 2004-02-18 | 2005-09-02 | Iichiro Shimomura | 低アディポネクチン血症予防・治療剤 |
| JP4834824B2 (ja) * | 2004-07-08 | 2011-12-14 | 独立行政法人産業技術総合研究所 | アディポネクチン産生増強剤 |
| JP2010018522A (ja) * | 2007-03-23 | 2010-01-28 | Hiroshima Univ | アディポネクチン産生促進剤 |
| JP5294165B2 (ja) * | 2007-03-23 | 2013-09-18 | ナガセケムテックス株式会社 | アディポネクチン上昇剤 |
| CN101301455A (zh) * | 2008-07-01 | 2008-11-12 | 崔井朝 | 一种治疗高脂血症的中药复方姜黄固体分散体 |
| JP2011063543A (ja) * | 2009-09-17 | 2011-03-31 | Kao Corp | アディポネクチン増加剤 |
| KR101702702B1 (ko) * | 2011-01-10 | 2017-02-03 | 무하메드 마제에드 | 칼레빈 ａ의 항-비만 가능성 |
-
2014
- 2014-04-23 US US14/259,404 patent/US9668999B2/en active Active
- 2014-04-29 AU AU2014202312A patent/AU2014202312B2/en not_active Ceased
- 2014-05-01 CA CA2850999A patent/CA2850999C/en active Active
- 2014-05-01 CA CA2963383A patent/CA2963383C/en active Active
- 2014-05-02 JP JP2014095457A patent/JP6263707B2/ja not_active Expired - Fee Related
- 2014-05-08 PL PL14167512T patent/PL2937084T3/pl unknown
- 2014-05-08 EP EP14167512.4A patent/EP2937084B1/en active Active
- 2014-06-10 KR KR1020140070179A patent/KR101647549B1/ko not_active Expired - Fee Related
- 2014-07-25 MY MYPI2014002207A patent/MY170067A/en unknown
- 2014-08-26 PH PH12014000244A patent/PH12014000244A1/en unknown
- 2014-09-03 TW TW103130375A patent/TWI622394B/zh not_active IP Right Cessation
- 2014-09-17 EA EA201491545A patent/EA027148B1/ru unknown
-
2015
- 2015-03-03 US US14/637,081 patent/US9610273B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150122552A (ko) | 2015-11-02 |
| US9610273B2 (en) | 2017-04-04 |
| CA2963383C (en) | 2018-12-04 |
| KR101647549B1 (ko) | 2016-08-10 |
| NZ624269A (en) | 2014-12-24 |
| TW201540295A (zh) | 2015-11-01 |
| MY170067A (en) | 2019-07-03 |
| CA2850999A1 (en) | 2015-10-23 |
| PH12014000244B1 (en) | 2016-08-08 |
| EA201491545A1 (ru) | 2015-10-30 |
| EP2937084A1 (en) | 2015-10-28 |
| JP2015209424A (ja) | 2015-11-24 |
| US9668999B2 (en) | 2017-06-06 |
| TWI622394B (zh) | 2018-05-01 |
| CA2963383A1 (en) | 2015-10-23 |
| AU2014202312B2 (en) | 2018-02-22 |
| CA2850999C (en) | 2018-04-03 |
| EA027148B1 (ru) | 2017-06-30 |
| PH12014000244A1 (en) | 2016-08-08 |
| AU2014202312A1 (en) | 2015-11-12 |
| US20150306060A1 (en) | 2015-10-29 |
| PL2937084T3 (pl) | 2017-05-31 |
| US20150306059A1 (en) | 2015-10-29 |
| EP2937084B1 (en) | 2016-11-30 |
| HK1210590A1 (en) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Effect of betaine on reducing body fat—a systematic review and meta-analysis of randomized controlled trials | |
| Le et al. | Parenteral fish-oil–based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition–dependent children | |
| Tomaszewska et al. | Cholesterol content, fatty acid profile and health lipid indices in the egg yolk of eggs from hens at the end of the laying cycle, following alpha-ketoglutarate supplementation | |
| Fu et al. | Lipid extract from hard-shelled mussel (Mytilus coruscus) improves clinical conditions of patients with rheumatoid arthritis: a randomized controlled trial | |
| JP6263707B2 (ja) | 高コレステロール血症の治療方法 | |
| Ji et al. | Using extract from the stems and leaves of Yizhi (Alpiniae oxyphyllae) as feed additive increases meat quality and intestinal health in ducks | |
| JP2011157350A (ja) | 液状組成物 | |
| Herrero-Encinas et al. | Diet supplementation with a bioactive pomace extract from Olea europaea partially mitigates negative effects on gut health arising from a short-term fasting period in broiler chickens | |
| Mirtha et al. | The effect of foot exercise on diabetic patients with foot ulcer: An Evidence-based case report | |
| Wu et al. | Effects of bone marrow mesenchymal stem cells on the cardiac function and immune system of mice with endotoxemia | |
| Reis et al. | Maternal supplementation with cow’s milk naturally enriched with pufa alters the metabolism of sows and the fatty acid profile of the offspring | |
| Murshed et al. | The anticoccidial effects of the poultry bile against Eimeria papillata oocysts of mice: In vitro study | |
| Amari et al. | Comparison of Three Different Balanced Sedative-Anaesthetic Protocols in Captive Baboons (Papio hamadryas) | |
| HK1210590B (en) | Method for the treatment of hypercholesterolemia | |
| JP2017176171A (ja) | フコキサンチンをフコキサンチノール及びアマロウシアキサンチンａの形態で蓄積させた鶏卵、及び、それを用いた機能性加工食品、抗肥満材、除脂肪体重増加剤、並びに、鶏卵の産生方法 | |
| Wang et al. | Consumption of Citric Acid by Bees Promotes the Gland Development and Enhances Royal Jelly Quality | |
| NZ624269B (en) | Method for the treatment of hypercholesterolemia | |
| EA032116B1 (ru) | Новое применение n,n-бис-2-меркаптоэтил-изофталамида | |
| Huang et al. | Potential molecular mechanism of growth difference in large yellow croaker: metabolomic and metagenomic analyses | |
| Floege | Noninvasive surveillance of kidney transplants: the heat is on | |
| Nagy et al. | The Biochemical Effects of Berberine on Hyperlipidemia and Insulin Resistance in Rats Fed High Fat Diet. | |
| TWI581798B (zh) | 用於消耗體脂肪的組合物 | |
| TWI411439B (zh) | 毛木耳萃取物用於改善骨質疏鬆症及憂鬱症之用途 | |
| Elgendy et al. | LONG TERM POSTOPERATIVE CHANGES OF PHOSPHATE AND MAGNESIUM IN CHILDREN AND ADULTS UNDERGOING LIVING DONOR LIVER TRANSPLANTATION.: 1235 | |
| Sato et al. | IMPACT OF TACROLIMUS DOSAGE WITHIN THE FIRST POST-TRANSPLANT WEEK ON ACUTE CELLULAR REJECTION IN PEDIATRIC LIVING DONOR LIVER TRANSPLANTATION: 1086 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160413 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170711 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170925 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171025 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171025 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6263707 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |